AU2002213133A1 - Method of preparing a eukaryotic viral vector - Google Patents

Method of preparing a eukaryotic viral vector

Info

Publication number
AU2002213133A1
AU2002213133A1 AU2002213133A AU1313302A AU2002213133A1 AU 2002213133 A1 AU2002213133 A1 AU 2002213133A1 AU 2002213133 A AU2002213133 A AU 2002213133A AU 1313302 A AU1313302 A AU 1313302A AU 2002213133 A1 AU2002213133 A1 AU 2002213133A1
Authority
AU
Australia
Prior art keywords
preparing
viral vector
eukaryotic viral
eukaryotic
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002213133A
Inventor
C. Richter King
Imre Kovesdi
Duncan L Mcvey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genvec Inc
Original Assignee
Genvec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genvec Inc filed Critical Genvec Inc
Publication of AU2002213133A1 publication Critical patent/AU2002213133A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2795/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
AU2002213133A 2000-10-10 2001-10-10 Method of preparing a eukaryotic viral vector Abandoned AU2002213133A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09685914 2000-10-10
US09/685,914 US6573092B1 (en) 2000-10-10 2000-10-10 Method of preparing a eukaryotic viral vector
PCT/US2001/031845 WO2002031169A1 (en) 2000-10-10 2001-10-10 Method of preparing a eukaryotic viral vector

Publications (1)

Publication Number Publication Date
AU2002213133A1 true AU2002213133A1 (en) 2002-04-22

Family

ID=24754186

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002213133A Abandoned AU2002213133A1 (en) 2000-10-10 2001-10-10 Method of preparing a eukaryotic viral vector

Country Status (3)

Country Link
US (2) US6573092B1 (en)
AU (1) AU2002213133A1 (en)
WO (1) WO2002031169A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1649028B1 (en) * 2003-07-25 2012-08-22 Genvec, Inc. Adenoviral vector-based vaccines
WO2006039045A2 (en) * 2004-09-01 2006-04-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenoviral vectors able to transduce apcs, potential use in immune response generation
WO2006094106A2 (en) * 2005-02-28 2006-09-08 Sangamo Biosciences, Inc. Anti-angiogenic methods and compositions
US9651543B2 (en) 2005-08-31 2017-05-16 The United States Of America As Represented By The Secretary Of The Navy Malaria antigen screening method
US8450055B2 (en) * 2005-08-31 2013-05-28 The United States Of America As Represented By The Secretary Of The Navy Malaria antigen screening method
EP1951297A2 (en) * 2005-11-10 2008-08-06 GenVec, Inc. Adenoviral vector-based foot-and-mouth disease vaccine
WO2007089780A2 (en) * 2006-01-30 2007-08-09 Licentia, Ltd. Bmx/etk tyrosine kinase gene therapy materials and methods
EP3199630B1 (en) 2008-09-05 2019-05-08 President and Fellows of Harvard College Continuous directed evolution of proteins and nucleic acids
US20110015256A1 (en) * 2009-07-16 2011-01-20 Ihab Mamdouh Ishak Sadek Delivery of restriction endonucleases to treat hiv, cancer, and other medical conditions
US9394537B2 (en) 2010-12-22 2016-07-19 President And Fellows Of Harvard College Continuous directed evolution
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
EP3097196B1 (en) 2014-01-20 2019-09-11 President and Fellows of Harvard College Negative selection and stringency modulation in continuous evolution systems
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
US10920208B2 (en) 2014-10-22 2021-02-16 President And Fellows Of Harvard College Evolution of proteases
WO2016168631A1 (en) 2015-04-17 2016-10-20 President And Fellows Of Harvard College Vector-based mutagenesis system
WO2017015545A1 (en) 2015-07-22 2017-01-26 President And Fellows Of Harvard College Evolution of site-specific recombinases
WO2017015559A2 (en) 2015-07-23 2017-01-26 President And Fellows Of Harvard College Evolution of bt toxins
US10612011B2 (en) 2015-07-30 2020-04-07 President And Fellows Of Harvard College Evolution of TALENs
IL258821B (en) 2015-10-23 2022-07-01 Harvard College Nucleobase editors and uses thereof
IL264565B1 (en) 2016-08-03 2024-03-01 Harvard College Adenosine nucleobase editors and uses thereof
CA3033327A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
JP2019530464A (en) 2016-10-14 2019-10-24 プレジデント アンド フェローズ オブ ハーバード カレッジ Nucleobase editor AAV delivery
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
CN110914310A (en) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 Cytosine to guanine base editor
WO2018176009A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11447809B2 (en) 2017-07-06 2022-09-20 President And Fellows Of Harvard College Evolution of tRNA synthetases
WO2019023680A1 (en) 2017-07-28 2019-01-31 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
WO2019056002A1 (en) 2017-09-18 2019-03-21 President And Fellows Of Harvard College Continuous evolution for stabilized proteins
WO2019079347A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. Uses of adenosine base editors
US11913044B2 (en) 2018-06-14 2024-02-27 President And Fellows Of Harvard College Evolution of cytidine deaminases
WO2020191239A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
DE112021002672T5 (en) 2020-05-08 2023-04-13 President And Fellows Of Harvard College METHODS AND COMPOSITIONS FOR EDIT BOTH STRANDS SIMULTANEOUSLY OF A DOUBLE STRANDED NUCLEOTIDE TARGET SEQUENCE
WO2023168239A2 (en) * 2022-03-01 2023-09-07 The Board Of Regents Of The University Of Texas System Methods for identifying lilrb ligands and blocking antibodies

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4578079A (en) * 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
KR0131678B1 (en) * 1991-12-09 1998-04-17 유미꾸라 레이이찌 Stabilized parathyroid hormone composition
JP3717925B2 (en) * 1992-09-29 2005-11-16 ネクター セラピューティクス Pulmonary introduction of active fragments of parathyroid hormone
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
EP0784690B1 (en) 1994-06-10 2006-08-16 Genvec, Inc. Complementary adenoviral vector systems and cell lines
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5962311A (en) 1994-09-08 1999-10-05 Genvec, Inc. Short-shafted adenoviral fiber and its use
US5736388A (en) 1994-12-30 1998-04-07 Chada; Sunil Bacteriophage-mediated gene transfer systems capable of transfecting eukaryotic cells
FR2730504B1 (en) 1995-02-13 1997-03-28 Rhone Poulenc Rorer Sa PROCESS FOR THE PREPARATION OF RECOMBINANT ADENOVIRUS GENOMES
DK1445322T4 (en) 1995-06-15 2012-09-03 Crucell Holland Bv Packaging systems for human recombinant adenovirus for use in gene therapy
BR9612685A (en) 1995-11-28 1999-07-20 Genvec Inc Vectors and methods for gene transfer to cells
US5989845A (en) 1996-04-05 1999-11-23 Mercury Diagnostics, Inc. Diagnostic compositions and devices utilizing same
WO1998056937A2 (en) 1997-06-09 1998-12-17 Genvec, Inc. Chimeric vectors comprising a phage packaging site and a portion derived from the genome of a eukaryotic virus
EP1003895A2 (en) 1997-07-10 2000-05-31 Hepavec AG fur Gentherapie Cloning vectors for producing adenoviral minimal viruses
CA2830694C (en) 1997-09-05 2018-02-27 Genzyme Corporation Methods for generating high titer helper-free preparations of recombinant aav vectors
AU747609B2 (en) 1997-09-23 2002-05-16 Oxford Biomedica (Uk) Limited Expression of genes in hematopoietic stem cells in hischaemic conditions
GB9720465D0 (en) 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
AU749856B2 (en) * 1997-09-23 2002-07-04 Genvec, Inc. Plasmids for construction of eukaryotic viral vectors

Also Published As

Publication number Publication date
WO2002031169A1 (en) 2002-04-18
US20030203480A1 (en) 2003-10-30
US6908762B2 (en) 2005-06-21
US6573092B1 (en) 2003-06-03

Similar Documents

Publication Publication Date Title
AU2002213133A1 (en) Method of preparing a eukaryotic viral vector
AU2001281493A1 (en) Method of preparing a polymerizate
AU5604100A (en) Methods of preparing a microporous article
AUPR464601A0 (en) Shapes vector
AU2001247902A1 (en) Cpg reduced plasmids and viral vectors
AU2002332407A1 (en) Ultra-light rock-climbing wall
AU2002348151A1 (en) Viral vector production methods and compositions
AU6111000A (en) Inhibitors of viral helcase
AU2002241793A1 (en) Process for the preparation of organoclays
AU2001271150A1 (en) A method of communication
AU2001232054A1 (en) Vector
AU2001291162A1 (en) Production of viral vectors
AU7739000A (en) Temperature-sensitive regulation of viral vector production
AU2001266081A1 (en) Improvement of itraconazole bioavailability
AU2001254936A1 (en) Method of reinforcing structures
AU2001234980A1 (en) Methods of preparing and using a viral vector library
AU2002227035A1 (en) Methods of stabilizing fruit-concentrate powders
AU2001256675A1 (en) Method of preparing virus vector
AU2002229648A1 (en) A process for the preparation of citalopram
AU2827100A (en) Process for the preparation of phenylhydrazines
AU2000275763A1 (en) Expression of functional eukaryotic proteins
AU2002308986A1 (en) Process for preparation of a quinolinecarbaldehyde
AU2002224845A1 (en) Viral expression system
AU2691400A (en) Virus vector
AU6428201A (en) Process for the preparation of 1-substituted-cyclo-hexanecarbonyl halides